Related Experiment Video

Updated: May 10, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

What is the need for further intracoronary treatment?

R Erbel1, T Pop, J Meyer

  • 1Johannes Gutenberg Universität, Mainz, F.R.G.

European Heart Journal
|September 1, 1987
PubMed

Insights

Intracoronary treatments for acute myocardial infarction enhance reperfusion and reduce reocclusion. Percutaneous transluminal coronary angioplasty (PTCA) alongside thrombolysis offers significant benefits, especially in complex cases.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Myocardial Infarction Research

Background:

  • Acute myocardial infarction (AMI) management aims to restore coronary blood flow.
  • Timely reperfusion is critical for salvaging heart muscle and improving outcomes.
  • Existing therapies face challenges in achieving optimal reperfusion and preventing complications.

Purpose of the Study:

  • To evaluate the utility of intracoronary treatments in AMI.
  • To assess the role of percutaneous transluminal coronary angioplasty (PTCA) in conjunction with thrombolytic therapy.
  • To investigate the benefits in specific patient subsets, including those with cardiogenic shock and right ventricular infarction.

Main Methods:

  • Review of intracoronary treatment strategies for AMI.
  • Analysis of PTCA combined with thrombolytic therapy.
  • Comparison with intravenous thrombolytic therapy and elective PTCA.

Main Results:

  • Intracoronary treatment facilitates maximal reperfusion rates in AMI.
  • It effectively reduces the rates of reocclusion and reinfarction.
  • Improved coronary blood flow is achieved, maximizing myocardial salvage.

Conclusions:

  • Intracoronary therapies, particularly PTCA with thrombolysis, represent a significant advancement in AMI treatment.
  • This approach shows particular promise for patients with cardiogenic shock and right ventricular infarction.
  • Further cooperative studies are needed to definitively compare intracoronary PTCA with intravenous thrombolysis and elective PTCA.

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...